Toyobo cuts annual net profit forecast to ¥4 billion after pharmaceutical impairment
Toyobo lowered its consolidated net profit forecast for the year ending March 2027 by ¥3 billion to ¥4 billion, down 64% from the previous year. It booked a ¥6.5 billion impairment loss as declining pharmaceutical orders weakened profitability. The company raised its sales forecast to ¥440 billion and operating profit forecast to ¥27 billion, citing expanding sales of industrial films for AI servers and price revisions, while leaving its annual dividend forecast unchanged at ¥40 per share.